High-throughput screening strategy identifies compounds active against antibiotic-resistant bacteria
New Rochelle, May 11, 2016-A new study in which researchers rapidly screened more than 11,000 bioactive molecules for activity against an antibiotic-resistant strain of Klebsiella pneumoniae bacteria identified multiple compounds with potent antimicrobial activity. These active compounds included two existing drugs, azidothymidine, an antiviral used to treat HIV infection, and spectinomycin, an antibacterial agent used to treat gonorrhea, as reported in ASSAY and Drug Development Technologies, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the ASSAY and Drug Development Technologies website until June 11, 2016.
Kenneth Smith and James Kirby, Beth Israel Deaconess Medical Center, Boston, MA, describe a high-throughput screening (HTS) assay they developed that is capable of detecting either the direct antibiotic activity of small molecules or their ability to act as adjunctive treatments by synergistically restoring the effectiveness of an antibiotic drug to which bacteria have developed resistance.
The article "Validation of a High-Throughput Screening Assay for Identification of Adjunctive and Directly Acting Antimicrobials Targeting Carbapenem-Resistant Enterobacteriaceae" describes how HTS of large compound libraries could lead to the identification of more effective therapies against intractable and potentially life-threatening infections.
"The paper by Smith and Kirby exemplifies the importance of a carefully designed strategy for HTS and follow-up characterization of active compounds," says ASSAY and Drug Development Technologies Editor-in-Chief Andrew D. Napper, PhD, Associate Director, Nemours Center for Childhood Cancer Research, Head – High Throughput Screening/Drug Discovery Laboratory, and Senior Research Scientist, Nemours/A.I. duPont Hospital for Children (Wilmington, DE). "By implementing this strategy, these authors efficiently and unequivocally identified compounds with clinically important anti-bacterial activity."
About the Journal
ASSAY and Drug Development Technologies is an authoritative peer-reviewed journal published 10 times a year online with open access options and in print. Led by Editor-in-Chief Andrew D. Napper, PhD, Associate Director, Nemours Center for Childhood Cancer Research, Head – High Throughput Screening/Drug Discovery Laboratory, and Senior Research Scientist, Nemours/A.I. duPont Hospital for Children (Wilmington, DE), the Journal provides early-stage screening techniques and tools that enable identification and optimization of novel targets and lead compounds for new drug development. Complete tables of content and a sample issue may be viewed on the ASSAY and Drug Development Technologies website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Applied In Vitro Toxicology, OMICS: A Journal of Integrative Biology, and Genetic Testing and Molecular Biomarkers. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is on the Mary Ann Liebert, Inc., publishers website.